CN108350041A - 修饰的炭疽毒素保护性抗原 - Google Patents
修饰的炭疽毒素保护性抗原 Download PDFInfo
- Publication number
- CN108350041A CN108350041A CN201680062198.3A CN201680062198A CN108350041A CN 108350041 A CN108350041 A CN 108350041A CN 201680062198 A CN201680062198 A CN 201680062198A CN 108350041 A CN108350041 A CN 108350041A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- ser
- asn
- leu
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
- C07K14/325—Bacillus thuringiensis crystal peptides, i.e. delta-endotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562210771P | 2015-08-27 | 2015-08-27 | |
| US62/210,771 | 2015-08-27 | ||
| US201662323218P | 2016-04-15 | 2016-04-15 | |
| US62/323,218 | 2016-04-15 | ||
| PCT/US2016/048706 WO2017035359A1 (en) | 2015-08-27 | 2016-08-25 | Modified anthrax toxin protective antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108350041A true CN108350041A (zh) | 2018-07-31 |
Family
ID=56943920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680062198.3A Pending CN108350041A (zh) | 2015-08-27 | 2016-08-25 | 修饰的炭疽毒素保护性抗原 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10835593B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3341393B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6865211B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180073555A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108350041A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016311429C1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017035359A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117343942A (zh) * | 2023-12-06 | 2024-01-05 | 南京市食品药品监督检验院 | 一种pagA重组蛋白及其制备方法 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180073555A (ko) | 2015-08-27 | 2018-07-02 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 변형된 탄저균 독소 방어 항원 |
| CA3119599A1 (en) | 2018-11-16 | 2020-05-22 | Rapa Therapeutics, Llc | Als treatment using induced regulatory t (itreg) cells |
| EP4150060A4 (en) * | 2020-05-13 | 2024-06-19 | Rapa Therapeutics, LLC | TREATMENT OR PREVENTION OF PRO-INFLAMMATORY DISEASES OR CONDITIONS USING INDUCED REGULATORY T CELLS (IT) |
| JP7648075B2 (ja) * | 2020-11-27 | 2025-03-18 | 株式会社ダイセル | 融合タンパク質 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601351B1 (en) * | 2002-06-26 | 2009-10-13 | Human Genome Sciences, Inc. | Antibodies against protective antigen |
| WO2014134187A1 (en) * | 2013-02-26 | 2014-09-04 | The Regents Of The University Of California | Compositions and methods for the treatment of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1214340B1 (en) | 1999-09-24 | 2004-11-24 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors |
| WO2005090393A2 (en) * | 2004-02-09 | 2005-09-29 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Multimeric protein toxins to target cells having multiple identifying characteristics |
| US20100168012A1 (en) | 2006-12-14 | 2010-07-01 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | Human cancer therapy using engineered matrix metalloproteinase-activated anthrax lethal toxin that targets tumor vasculatuture |
| CN101215568B (zh) | 2008-01-18 | 2010-06-23 | 畿晋庆三联(北京)生物技术有限公司 | 抗炭疽多肽及其应用与制备方法 |
| US9890369B2 (en) | 2013-06-20 | 2018-02-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor |
| SG11201602012RA (en) | 2013-09-25 | 2016-04-28 | Pronutria Inc | Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof |
| KR20180073555A (ko) | 2015-08-27 | 2018-07-02 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 변형된 탄저균 독소 방어 항원 |
-
2016
- 2016-08-25 KR KR1020187008131A patent/KR20180073555A/ko not_active Ceased
- 2016-08-25 JP JP2018510419A patent/JP6865211B2/ja active Active
- 2016-08-25 EP EP16767065.2A patent/EP3341393B1/en active Active
- 2016-08-25 WO PCT/US2016/048706 patent/WO2017035359A1/en not_active Ceased
- 2016-08-25 CN CN201680062198.3A patent/CN108350041A/zh active Pending
- 2016-08-25 US US15/755,341 patent/US10835593B2/en active Active
- 2016-08-25 AU AU2016311429A patent/AU2016311429C1/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601351B1 (en) * | 2002-06-26 | 2009-10-13 | Human Genome Sciences, Inc. | Antibodies against protective antigen |
| WO2014134187A1 (en) * | 2013-02-26 | 2014-09-04 | The Regents Of The University Of California | Compositions and methods for the treatment of cancer |
Non-Patent Citations (4)
| Title |
|---|
| DIANE E. PETERS等: "Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities", 《TOXICOLOGY AND APPLIED PHARMACOLOGY》 * |
| M. J. ROSOVITZ等: "Alanine-scanning Mutations in Domain 4 of Anthrax Toxin Protective Antigen Reveal Residues Important for Binding to the Cellular Receptor and to a Neutralizing Monoclonal Antibody", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 * |
| MICHAEL MOUREZ等: "Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis", 《PNAS》 * |
| NONE: "UniProtKB-S5M0J7", 《UNIPROT DATABASE》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117343942A (zh) * | 2023-12-06 | 2024-01-05 | 南京市食品药品监督检验院 | 一种pagA重组蛋白及其制备方法 |
| CN117343942B (zh) * | 2023-12-06 | 2024-02-13 | 南京市食品药品监督检验院 | 一种pagA重组蛋白及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018527926A (ja) | 2018-09-27 |
| EP3341393A1 (en) | 2018-07-04 |
| US10835593B2 (en) | 2020-11-17 |
| KR20180073555A (ko) | 2018-07-02 |
| AU2016311429A1 (en) | 2018-04-19 |
| WO2017035359A1 (en) | 2017-03-02 |
| AU2016311429C1 (en) | 2021-10-07 |
| US20180250376A1 (en) | 2018-09-06 |
| JP6865211B2 (ja) | 2021-04-28 |
| AU2016311429B2 (en) | 2021-07-08 |
| CA2996767A1 (en) | 2017-03-02 |
| EP3341393B1 (en) | 2021-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3341393B1 (en) | Modified anthrax toxin protective antigen | |
| CN100488981C (zh) | 含有蛋白酶激活序列的气单胞菌溶素原及其应用 | |
| CN1195849C (zh) | April-具有生长效应的新的蛋白质 | |
| KR100607609B1 (ko) | Il-2 선택성 작용제 및 길항제 | |
| US20190328838A1 (en) | Compositions comprising il-2 fusion proteins and methods for treating neoplasia | |
| US8388933B2 (en) | Multimeric protein toxins to target cells having multiple identifying characteristics | |
| EP2130919A1 (en) | IL-21 antagonists | |
| KR20150035587A (ko) | 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물 | |
| US20100135901A1 (en) | Combination therapy | |
| JP7744621B2 (ja) | 切断されたモルモットl-アスパラギナーゼバリアントおよび使用の方法 | |
| CN102341407A (zh) | 作为补体抑制剂的经修饰的omci | |
| RO120919B1 (ro) | Proteină hematopoietină, moleculă de acid nucleiccare o codifică, compoziţie farmaceutică şi utilizarea proteinei | |
| CA2996767C (en) | Modified anthrax toxin protective antigen | |
| AU2015243297A1 (en) | Poxviral oncolytic vectors | |
| WO2023155872A1 (zh) | 一种实现生物活性分子其活性控释和缓释的方法及药物应用 | |
| JP4273234B2 (ja) | チオレドキシン改変体 | |
| CN1267450C (zh) | 新型人肿瘤坏死因子突变蛋白及其制法和用途 | |
| CN117417429A (zh) | 肿瘤微环境激活的细胞因子及其应用 | |
| HK1033956A1 (en) | Genetically modified tumor-targeted bacteria with reduced virulence | |
| HK1033956B (en) | Genetically modified tumor-targeted bacteria with reduced virulence | |
| Kreitman | IBC’s International Conference on novel therapeutic proteins for oncology (drug discovery and development) | |
| CN1913913A (zh) | Cab分子 | |
| CN1167502A (zh) | 人dna连接酶iii | |
| WO2010062982A1 (en) | Tumor-targeting co2-resistant salmonella |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180731 |